# A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

> **NCT05769855** · PHASE3 · COMPLETED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 294 (actual)

## Conditions studied

- Postsurgical Pain Management

## Interventions

- **DRUG:** HR18034
- **DRUG:** ropivacaine HCl
- **DRUG:** Sodium Chloride Physiological Solution

## Key facts

- **NCT ID:** NCT05769855
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-21
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769855, "A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05769855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*